To assess the long-term effects of zoledronate on fracture risk in postmenopausal women aged 50 to 60, specifically evaluating the influence of baseline variables and changes in bone mineral density (BMD) over time.
Key Findings:
Morphometric vertebral fractures were reduced by 58% in the zol-zol group and 57% in the zol-placebo group during years 5 to 10 (95% CI, 21%-77%).
Similar reductions were observed for any fractures and major osteoporotic fractures.
No significant interactions were found between treatment effects and baseline variables or changes in BMD.
Interpretation:
Zoledronate appears to provide greater fracture risk reduction in the second half of the study period, suggesting that less frequent administration may be effective for low-risk women, potentially reducing the need for routine monitoring.
Limitations:
The study focused only on postmenopausal women aged 50 to 60, limiting generalizability.
No other interventions (e.g., vitamin D or calcium) were provided, which may affect outcomes.
The sample lacked diversity, which may limit the applicability of findings to broader populations.
Conclusion:
Zoledronate administered every 5 or 10 years can effectively reduce fracture risk in low-risk postmenopausal women, indicating that routine BMD monitoring may not be necessary for this group, thus simplifying treatment strategies.
by Mark J Bolland, Zaynah Nisa, Anna Mellar, Chiara Gasteiger, Veronica Pinel, Borislav Mihov, Sonja Bastin, Andrew Grey, Ian R Reid, Greg Gamble, Anne Horne
